These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 7870872)
1. Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3'-trifluoromethyl phenyl) 1,4-dihydro 3-amino 4-oxo 6-methyl pyridazine. 1. Acute and in vitro effects. Assié MB; Chopin P; Stenger A; Palmier C; Briley M Psychopharmacology (Berl); 1993; 110(1-2):13-8. PubMed ID: 7870872 [TBL] [Abstract][Full Text] [Related]
2. Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3'-trifluoromethyl phenyl) 1, 4-dihydro 3-amino 4-oxo 6-methyl pyridazine. 2. Evaluation of its tolerance and dependence producing potential and of its effects on benzodiazepine withdrawal in the elevated plus-maze test in rats. Chopin P; Assié MB; Briley M Psychopharmacology (Berl); 1993; 110(1-2):19-26. PubMed ID: 7870883 [TBL] [Abstract][Full Text] [Related]
3. F 2692: flumazenil-reversible anxiolytic effects but inactive on [3H]-Ro 15-4513 binding. File SE; Andrews N Pharmacol Biochem Behav; 1994 May; 48(1):223-7. PubMed ID: 7913225 [TBL] [Abstract][Full Text] [Related]
4. The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models. Artaiz I; Romero G; Zazpe A; Monge A; Calderó JM; Roca J; Lasheras B; Del Río J Psychopharmacology (Berl); 1995 Jan; 117(2):137-48. PubMed ID: 7753959 [TBL] [Abstract][Full Text] [Related]
5. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. Atack JR; Wafford KA; Tye SJ; Cook SM; Sohal B; Pike A; Sur C; Melillo D; Bristow L; Bromidge F; Ragan I; Kerby J; Street L; Carling R; Castro JL; Whiting P; Dawson GR; McKernan RM J Pharmacol Exp Ther; 2006 Jan; 316(1):410-22. PubMed ID: 16183706 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of the novel putative anxiolytic agent 1-amino-5-bromouracil. Imaizumi M; Miyazaki S; Watanabe Y; Machida H Arzneimittelforschung; 1994 Mar; 44(3):285-8. PubMed ID: 7910744 [TBL] [Abstract][Full Text] [Related]
8. New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. Griebel G; Perrault G; Letang V; Granger P; Avenet P; Schoemaker H; Sanger DJ Psychopharmacology (Berl); 1999 Sep; 146(2):205-13. PubMed ID: 10525757 [TBL] [Abstract][Full Text] [Related]
9. The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors. Popik P; Kostakis E; Krawczyk M; Nowak G; Szewczyk B; Krieter P; Chen Z; Russek SJ; Gibbs TT; Farb DH; Skolnick P; Lippa AS; Basile AS J Pharmacol Exp Ther; 2006 Dec; 319(3):1244-52. PubMed ID: 16971504 [TBL] [Abstract][Full Text] [Related]
10. Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593. Wieland S; Belluzzi J; Hawkinson JE; Hogenkamp D; Upasani R; Stein L; Wood PL; Gee KW; Lan NC Psychopharmacology (Berl); 1997 Nov; 134(1):46-54. PubMed ID: 9399366 [TBL] [Abstract][Full Text] [Related]
11. Like diazepam, CL 218,872, a selective ligand for the benzodiazepine omega 1 receptor subtype, impairs place learning in the Morris water maze. McNamara RK; Skelton RW Psychopharmacology (Berl); 1992; 107(2-3):347-51. PubMed ID: 1352055 [TBL] [Abstract][Full Text] [Related]
12. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Przegaliński E; Tatarczyńska E; Chojnacka-Wójcik E Neuropharmacology; 2000 Jul; 39(10):1858-64. PubMed ID: 10884566 [TBL] [Abstract][Full Text] [Related]
13. The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist. Yasumatsu H; Morimoto Y; Yamamoto Y; Takehara S; Fukuda T; Nakao T; Setoguchi M Br J Pharmacol; 1994 Apr; 111(4):1170-8. PubMed ID: 7913372 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests. Jastrzębska-Więsek M; Siwek A; Partyka A; Kubacka M; Mogilski S; Wasik A; Kołaczkowski M; Wesołowska A Neuropharmacology; 2014 Oct; 85():253-62. PubMed ID: 24905144 [TBL] [Abstract][Full Text] [Related]
15. Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor. Langen B; Egerland U; Bernöster K; Dost R; Unverferth K; Rundfeldt C J Pharmacol Exp Ther; 2005 Aug; 314(2):717-24. PubMed ID: 15860576 [TBL] [Abstract][Full Text] [Related]
16. Flavan-3-ol derivatives are positive modulators of GABA(A) receptors with higher efficacy for the alpha(2) subtype and anxiolytic action in mice. Fernandez SP; Mewett KN; Hanrahan JR; Chebib M; Johnston GA Neuropharmacology; 2008 Oct; 55(5):900-7. PubMed ID: 18657554 [TBL] [Abstract][Full Text] [Related]
17. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Chopin P; Briley M Psychopharmacology (Berl); 1993; 110(4):409-14. PubMed ID: 7870910 [TBL] [Abstract][Full Text] [Related]
18. Ethyl loflazepate: a prodrug from the benzodiazepine series designed to dissociate anxiolytic and sedative activities. Chambon JP; Perio A; Demarne H; Hallot A; Dantzer R; Roncucci R; Bizière K Arzneimittelforschung; 1985; 35(10):1573-7. PubMed ID: 2866771 [TBL] [Abstract][Full Text] [Related]
19. Changes in benzodiazepine-GABA receptor coupling in an accumbens-habenula circuit after chronic diazepam treatment. Brett RR; Pratt JA Br J Pharmacol; 1995 Nov; 116(5):2375-84. PubMed ID: 8581272 [TBL] [Abstract][Full Text] [Related]